We are live on ! Find out more
T. Rowe Price Associates

T. Rowe Price Associates Portfolio holdings

AUM $865B
1-Year Est. Return 30.76%
 

T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.

This Fund
S&P 500
This Quarter Est. Return
+3.23%
1 Year Est. Return
+30.76%
3 Year Est. Return
+117.39%
5 Year Est. Return
+143.85%
10 Year Est. Return
+1,089.89%
AUM
$472B
AUM Growth
+$3.53B
Cap. Flow
-$5.2B
Cap. Flow %
-1.1%
Top 10 Hldgs %
16.24%
Holding
2,596
New
95
Increased
1,094
Reduced
954
Closed
84

Top Sells

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$1.2B
2
AGN
Allergan plc
AGN
+$1.03B
3
GILD icon
Gilead Sciences
GILD
+$917M
4
PFE icon
Pfizer
PFE
+$901M
5
NKE icon
Nike
NKE
+$872M

Sector Composition

Rank Sector Weight
1 Healthcare 19.88%
2 Consumer Discretionary 14.86%
3 Financials 14.2%
4 Technology 12.51%
5 Industrials 9.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
AWRE icon
2376
Aware
AWRE
$27M
$126K ﹤0.01%
29,000
DGII icon
2377
Digi International
DGII
$3.21B
$126K ﹤0.01%
11,741
-19
-0.2% -$196
EFOI icon
2378
Energy Focus
EFOI
$19.2M
$126K ﹤0.01%
+575
New +$136K
FCF icon
2379
First Commonwealth Financial
FCF
$2.19B
$124K ﹤0.01%
13,500
AEGR
2380
DELISTED
Aegerion Pharmaceuticals
AEGR
$122K ﹤0.01%
81,700
+71,000
+664% +$162K
ACTG icon
2381
Acacia Research
ACTG
$452M
$121K ﹤0.01%
+27,400
New +$126K
PCTI
2382
DELISTED
PCTEL, Inc. Common Stock
PCTI
$121K ﹤0.01%
25,700
VHC icon
2383
VirnetX Holding Corp
VHC
$67.6M
$120K ﹤0.01%
1,500
SGI
2384
DELISTED
Silicon Graphics Intl.
SGI
$120K ﹤0.01%
23,800
PES
2385
DELISTED
Pioneer Energy Services Corp.
PES
$119K ﹤0.01%
+25,900
New +$85.2K
CCO icon
2386
Clear Channel Outdoor Holdings
CCO
$1.2B
$118K ﹤0.01%
18,980
-18
-0.1% -$102
BSF
2387
DELISTED
Bear State Financial, Inc.
BSF
$118K ﹤0.01%
12,510
XCRA
2388
DELISTED
Xcerra Corporation
XCRA
$117K ﹤0.01%
20,299
ACTA
2389
DELISTED
Actua Corp
ACTA
$116K ﹤0.01%
12,800
CACB
2390
DELISTED
Cascade Bancorp
CACB
$116K ﹤0.01%
+20,886
New +$119K
LYTS icon
2391
LSI Industries
LYTS
$899M
$115K ﹤0.01%
10,399
-26
-0.2% -$309
REFR icon
2392
Research Frontiers
REFR
$16.1M
$115K ﹤0.01%
31,600
CECO icon
2393
Ceco Environmental
CECO
$4.6B
$114K ﹤0.01%
13,001
GNE icon
2394
Genie Energy
GNE
$385M
$114K ﹤0.01%
16,842
SXC icon
2395
SunCoke Energy
SXC
$791M
$113K ﹤0.01%
19,500
GIFI
2396
DELISTED
Gulf Island Fabrication
GIFI
$112K ﹤0.01%
16,200
-491,266
-97% -$3.51M
PACB icon
2397
Pacific Biosciences
PACB
$351M
$112K ﹤0.01%
15,900
-15,000
-49% -$137K
IMUX icon
2398
Immunic
IMUX
$226M
$111K ﹤0.01%
45
INWK
2399
DELISTED
InnerWorkings, Inc.
INWK
$111K ﹤0.01%
13,400
CYTR
2400
DELISTED
CytRx Corp
CYTR
$111K ﹤0.01%
8,317
-3,283
-28% -$54.6K

Similar funds

T. Rowe Price Associates's Q2 2016 Portfolio in Review

As of Q2 2016, T. Rowe Price Associates held 2,596 positions worth $472B, up 0.75% from $468B the previous quarter. Its ten largest holdings account for 16% of the portfolio.

T. Rowe Price Associates's Q2 2016 filing shows 95 new, 1,094 increased, 954 reduced and 84 closed positions. Its largest new stake was American Tower Corporation: 2,223,765 shares worth $246M. The largest sale was Alexion Pharmaceuticals, an estimated $1.2B.

By sector, the portfolio is most concentrated in Healthcare at 20% of assets, down from 21% a quarter earlier, followed by Consumer Discretionary and Financials.

  • T. Rowe Price Associates's largest Q2 2016 buy was American Tower Corporation: 2,223,765 shares worth $246M.
  • T. Rowe Price Associates added most to Mondelez International in Q2 2016, an estimated $841M increase.
  • T. Rowe Price Associates's biggest Q2 2016 reduction was Alexion Pharmaceuticals, cutting an estimated $1.2B.
  • T. Rowe Price Associates fully exited BAXALTA INC COM STK (DE) in Q2 2016, selling an estimated $750M.
  • T. Rowe Price Associates's ten largest holdings make up 16% of its $472B portfolio in Q2 2016.
  • T. Rowe Price Associates opened 95 new positions and closed 84 in Q2 2016.
  • T. Rowe Price Associates's portfolio value rose 0.75% quarter-over-quarter to $472B.

Based on T. Rowe Price Associates's 13F filing for Q2 2016, filed 15 Aug 2016.